Edition:
United States

H Lundbeck A/S (LUN.CO)

LUN.CO on Copenhagen Stock Exchange

383.80DKK
21 Jul 2017
Change (% chg)

kr.-0.40 (-0.10%)
Prev Close
kr.384.20
Open
kr.384.30
Day's High
kr.388.00
Day's Low
kr.383.20
Volume
186,216
Avg. Vol
523,020
52-wk High
kr.396.70
52-wk Low
kr.212.70

LUN.CO

Chart for LUN.CO

About

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and... (more)

Overall

Beta: 0.86
Market Cap(Mil.): kr.76,169.17
Shares Outstanding(Mil.): 198.46
Dividend: 2.45
Yield (%): 0.64

Financials

  LUN.CO Industry Sector
P/E (TTM): 46.99 11.79 15.85
EPS (TTM): 8.17 -- --
ROI: 12.55 -10.04 -8.31
ROE: 17.38 -9.89 -7.95

BRIEF-Lundbeck, Takeda receive CRL from FDA for Trintellix (vortioxetine) sNDA

* Lundbeck and Takeda receive complete response letter from the FDA for Trintellix® (vortioxetine) sNDA

Jun 22 2017

BRIEF-Lundbeck obtains rights to research in Alzheimer's disease

* SIGNS DEAL WITH BIOTECH COMPANY IMMUNOBRAIN CHECKPOINT, INC. (IBC) FOR RIGHTS TO RESEARCH IN TREATMENT OF ALZHEIMER'S DISEASE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 06 2017

UPDATE 1-Lundbeck raises earnings guidance for the fourth time in 12 months

May 10 Danish drugmaker Lundbeck raised its financial guidance for the fourth time in 12 months as sales of its anti-epileptic drug Sabril was not dented by copycat competition, as Lundbeck had expected, its chief executive said on Wedneday.

May 10 2017

BRIEF-Lundbeck Q1 EBIT at DKK 1.01 Billion, above expectations

* 2017 GUIDANCE RAISED BASED ON STRONG REVENUE GROWTH AND IMPROVED PROFITABILITY

May 10 2017

BRIEF-Lundbeck enters a conditional agreement to sell part of its headquarters

* LUNDBECK ENTERS A CONDITIONAL AGREEMENT AND DIVESTS PART OF ITS HEADQUARTERS IN COPENHAGEN AND EXPECTS TO RAISE ITS FINANCIAL GUIDANCE BY DKK 200 MILLION

May 05 2017

BRIEF-Otsuka and Lundbeck announce top-line results from two phase III clinical trials

* OTSUKA AND LUNDBECK ANNOUNCE IMPROVEMENT OF AGITATION SYMPTOMS RELATED TO ALZHEIMER’S-TYPE DEMENTIA FOLLOWING TREATMENT WITH BREXPIPRAZOLE RELATIVE TO PLACEBO

May 02 2017

BRIEF-Health Canada approves Otsuka and Lundbeck's REXULTI as a treatment for schizophrenia in adults

* Health Canada approves Otsuka and Lundbeck's REXULTI(tm) (brexpiprazole) as a treatment for schizophrenia in adults

Feb 17 2017

Lundbeck gives up on Alzheimer's drug, rival to Axovant pill

Two remaining late-stage clinical trials testing an experimental Alzheimer's drug from Denmark's Lundbeck have failed, scuppering hopes for the medicine and underscoring the difficulty of developing such treatments.

Feb 08 2017

Lundbeck gives up on Alzheimer's drug, rival to Axovant pill

Feb 8 Two remaining late-stage clinical trials testing an experimental Alzheimer's drug from Denmark's Lundbeck have failed, scuppering hopes for the medicine and underscoring the difficulty of developing such treatments.

Feb 08 2017

BRIEF-Lundbeck CEO says not concerned about Trump policies

* Not concerned about the policies of U.S. President Donald Trump.

Feb 08 2017

Earnings vs. Estimates